IGF2 and cancer: Overall the genomic landscape was stable, with pathogenic or likely pathogenic alterations being identified in 51 cancer genes, with 9 (18%) of them showing alterations being recurrent across different samples (MYCN, CDKN2A/2B, CDK4, GLI1, AKT1, IGF2, MED12, NCOR2) (Fig. 1).